RU2386639C2 - Связывающие молекулы, обладающие терапевтической активностью - Google Patents
Связывающие молекулы, обладающие терапевтической активностью Download PDFInfo
- Publication number
- RU2386639C2 RU2386639C2 RU2006112598/13A RU2006112598A RU2386639C2 RU 2386639 C2 RU2386639 C2 RU 2386639C2 RU 2006112598/13 A RU2006112598/13 A RU 2006112598/13A RU 2006112598 A RU2006112598 A RU 2006112598A RU 2386639 C2 RU2386639 C2 RU 2386639C2
- Authority
- RU
- Russia
- Prior art keywords
- seq
- polypeptide
- sequence
- antibody
- cd45ro
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Изобретение относится к области иммунологии и биотехнологии. Описаны варианты гуманизированного антитела к CD45RO/RB, несущие легкую и тяжелую цепь. Раскрыты варианты: выделенного полинуклеотида, кодирующего антитела, экспрессионного вектора, содержащего полинуклеотид и клетки-хозяина, включающей вектор экспрессии. Описано применение антитела для лечения и/или профилактики различных заболеваний, в том числе в составе фармацевтической композиции. Использование изобретения обеспечивает антитела, распознающие как CD45RO, так и CD45RB, что может найти применение в медицине. 7 н. и 2 з.п. ф-лы, 14 ил., 2 табл.
Description
Claims (9)
1. Гуманизированное антитело к CD45RO/RB, содержащее полипептид, имеющий последовательность SEQ ID NO:31 или SEQ ID NO:32, и полипептид, имеющий последовательность SEQ ID NO:7 или SEQ ID NO:8.
2. Гуманизированное антитело к CD45RO/RB, которое содержит
полипептид, имеющий последовательность SEQ ID NO:31, и полипептид, имеющий последовательность SEQ ID NO:7,
полипептид, имеющий последовательность SEQ ID NO:31, и полипептид, имеющий последовательность SEQ ID NO:8,
полипептид, имеющий последовательность SEQ ID NO:32, и полипептид, имеющий последовательность SEQ ID NO:7, или
полипептид, имеющий последовательность SEQ ID NO:32, и полипептид, имеющий последовательность SEQ ID NO:8.
полипептид, имеющий последовательность SEQ ID NO:31, и полипептид, имеющий последовательность SEQ ID NO:7,
полипептид, имеющий последовательность SEQ ID NO:31, и полипептид, имеющий последовательность SEQ ID NO:8,
полипептид, имеющий последовательность SEQ ID NO:32, и полипептид, имеющий последовательность SEQ ID NO:7, или
полипептид, имеющий последовательность SEQ ID NO:32, и полипептид, имеющий последовательность SEQ ID NO:8.
3. Выделенный полинуклеотид, кодирующий антитело по одному из пп.1 и 2.
4. Экспрессионный вектор, содержащий полинуклеотиды по п.3.
5. Выделенная эукариотическая клетка-хозяин, которая включает систему экспрессии по п.4.
6. Применение гуманизированного антитела по одному из пп.1 и 2 или выделенного полинуклеотида по п.3 для лечения и/или профилактики аутоиммунных заболеваний, отторжения трансплантата, псориаза, дерматита, воспалительного заболевания кишечника и/или аллергий.
7. Применение по п.6 для лечения и/или профилактики реакции трансплантат против хозяина (РТПХ).
8. Применение гуманизированного антитела по п.6 для приготовления лекарственного средства, предназначенного для лечения отторжения трансплантата панкреатических островковых клеток.
9. Фармацевтическая композиция для лечения и/или профилактики аутоиммунных заболеваний, отторжения трансплантата, псориаза, дерматита, воспалительного заболевания кишечника и/или аллергий, включающая терапевтически эффективное количество гуманизированнного антитела по одному из пп.1-3 в сочетании по меньшей мере с одним фармацевтически приемлемым носителем или разбавителем.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/666,332 | 2003-09-18 | ||
US10/666,332 US20050069538A1 (en) | 2003-09-18 | 2003-09-18 | Therapeutic binding molecules |
GB0414309.5 | 2004-06-25 | ||
GB0414309A GB0414309D0 (en) | 2004-06-25 | 2004-06-25 | Organic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2006112598A RU2006112598A (ru) | 2007-10-27 |
RU2386639C2 true RU2386639C2 (ru) | 2010-04-20 |
Family
ID=34315457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006112598/13A RU2386639C2 (ru) | 2003-09-18 | 2004-09-17 | Связывающие молекулы, обладающие терапевтической активностью |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP1664122B1 (ru) |
JP (1) | JP4762142B2 (ru) |
KR (1) | KR20060079232A (ru) |
AR (2) | AR045765A1 (ru) |
AT (1) | ATE461219T1 (ru) |
AU (1) | AU2004272289B2 (ru) |
BR (1) | BRPI0414515A (ru) |
CA (1) | CA2537217A1 (ru) |
CY (1) | CY1110033T1 (ru) |
DE (1) | DE602004026081D1 (ru) |
DK (1) | DK1664122T3 (ru) |
EC (1) | ECSP066432A (ru) |
ES (1) | ES2341341T3 (ru) |
HK (1) | HK1091844A1 (ru) |
HR (1) | HRP20100334T1 (ru) |
IL (1) | IL173820A0 (ru) |
IS (1) | IS8397A (ru) |
MA (1) | MA28041A1 (ru) |
MY (1) | MY143963A (ru) |
NO (1) | NO20061681L (ru) |
NZ (1) | NZ545605A (ru) |
PE (1) | PE20060019A1 (ru) |
PL (1) | PL1664122T3 (ru) |
PT (1) | PT1664122E (ru) |
RU (1) | RU2386639C2 (ru) |
SI (1) | SI1664122T1 (ru) |
TN (1) | TNSN06087A1 (ru) |
TW (1) | TW200521231A (ru) |
WO (1) | WO2005026210A2 (ru) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2502631A1 (en) | 2011-03-22 | 2012-09-26 | Medizinische Hochschule Hannover | Immune suppressor and its use |
GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
CN105886609B (zh) * | 2015-02-17 | 2020-02-21 | 陈沛隆 | 药物不良反应风险评估方法及其装置 |
CA2982115A1 (en) | 2015-04-06 | 2016-10-13 | President And Fellows Of Harvard College | Compositions and methods for non-myeloablative conditioning |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
JP2019522050A (ja) * | 2016-06-17 | 2019-08-08 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | 細胞の枯渇のための組成物および方法 |
JP2020522254A (ja) | 2017-05-31 | 2020-07-30 | エルスター セラピューティクス, インコーポレイテッド | 骨髄増殖性白血病(mpl)タンパク質に結合する多特異性分子およびその使用 |
WO2022079199A1 (en) | 2020-10-15 | 2022-04-21 | UCB Biopharma SRL | Binding molecules that multimerise cd45 |
IL303270A (en) | 2020-12-21 | 2023-07-01 | Allogene Therapeutics Inc | The CD45–GATE vehicle activates a protease |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6106834A (en) * | 1993-06-02 | 2000-08-22 | Research Corporation Technologies, Inc. | Use of anti-CD45 leukocyte antigen antibodies for immunomodulation |
GB0103389D0 (en) * | 2001-02-12 | 2001-03-28 | Novartis Ag | Organic compounds |
-
2004
- 2004-09-17 CA CA002537217A patent/CA2537217A1/en not_active Abandoned
- 2004-09-17 WO PCT/EP2004/010471 patent/WO2005026210A2/en active Application Filing
- 2004-09-17 BR BRPI0414515-1A patent/BRPI0414515A/pt not_active Application Discontinuation
- 2004-09-17 RU RU2006112598/13A patent/RU2386639C2/ru not_active IP Right Cessation
- 2004-09-17 TW TW093128255A patent/TW200521231A/zh unknown
- 2004-09-17 AU AU2004272289A patent/AU2004272289B2/en not_active Ceased
- 2004-09-17 KR KR1020067005352A patent/KR20060079232A/ko not_active Application Discontinuation
- 2004-09-17 ES ES04765363T patent/ES2341341T3/es active Active
- 2004-09-17 PT PT04765363T patent/PT1664122E/pt unknown
- 2004-09-17 NZ NZ545605A patent/NZ545605A/en not_active IP Right Cessation
- 2004-09-17 PL PL04765363T patent/PL1664122T3/pl unknown
- 2004-09-17 EP EP04765363A patent/EP1664122B1/en active Active
- 2004-09-17 JP JP2006526599A patent/JP4762142B2/ja not_active Expired - Fee Related
- 2004-09-17 AR ARP040103362A patent/AR045765A1/es active IP Right Grant
- 2004-09-17 MY MYPI20043795A patent/MY143963A/en unknown
- 2004-09-17 AT AT04765363T patent/ATE461219T1/de active
- 2004-09-17 DE DE602004026081T patent/DE602004026081D1/de active Active
- 2004-09-17 SI SI200431411T patent/SI1664122T1/sl unknown
- 2004-09-17 PE PE2004000909A patent/PE20060019A1/es not_active Application Discontinuation
- 2004-09-17 DK DK04765363.9T patent/DK1664122T3/da active
-
2006
- 2006-02-20 IL IL173820A patent/IL173820A0/en not_active IP Right Cessation
- 2006-03-14 MA MA28875A patent/MA28041A1/fr unknown
- 2006-03-17 EC EC2006006432A patent/ECSP066432A/es unknown
- 2006-03-17 TN TNP2006000087A patent/TNSN06087A1/en unknown
- 2006-04-03 IS IS8397A patent/IS8397A/is unknown
- 2006-04-12 NO NO20061681A patent/NO20061681L/no not_active Application Discontinuation
- 2006-11-09 HK HK06112334.4A patent/HK1091844A1/xx unknown
-
2010
- 2010-05-14 CY CY20101100424T patent/CY1110033T1/el unknown
- 2010-06-10 HR HR20100334T patent/HRP20100334T1/hr unknown
- 2010-12-14 AR ARP100104624A patent/AR079458A2/es not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
Friend et. al., "Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection", Transplantation, vol.68 (11), стр.1632-1637, 1999. * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2386639C2 (ru) | Связывающие молекулы, обладающие терапевтической активностью | |
RU2207878C2 (ru) | "очеловеченные" антитела против gp39 человека, композиции, содержащие эти антитела, и их терапевтическое использование | |
Harrison et al. | Research strategies to improve snakebite treatment: Challenges and progress | |
RU2003126168A (ru) | Терапевтические связывающие молекулы | |
US5639455A (en) | Immunosuppressant | |
TWI264467B (en) | Human anti-CD40 antibodies and methods of making and using same | |
AU730498B2 (en) | Treatment of autoimmune disease, including aids | |
RU2421464C2 (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
RU2437893C2 (ru) | Варианты il-7 со сниженной иммуногенностью | |
US20210268078A1 (en) | Systems, compositions, and methods for transplantation | |
RU2000109255A (ru) | "очеловеченные" антитела против gp39 человека, композиции, содержащие эти антитела, и их терапевтическое использование | |
US20060182747A1 (en) | Treatment of autism | |
Luger et al. | A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation | |
EP1461081A4 (en) | ANTI-CD45RB ANTIBODY FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AND TRANSPLANT ABLUSION | |
RU2000124084A (ru) | Химерное антитело, которое связывается с CD40 человека (варианты), молекула нуклеиновой кислоты (варианты), вектор экспрессии (варианты), гуманизированное антитело (варианты), фармацевтическая композиция для лечения заболевания, опосредованного Т-клетками (варианты), способ лечения больного от заболевания, опосредованного Т-клетками (варианты) | |
HUP9902327A2 (hu) | Humán gp39-elleni humanizált antitestek, az antitesteket tartalmazó készítmények és terápiás alkalmazásuk | |
CN111164105A (zh) | 抗pacap抗体 | |
WO2004067549A2 (de) | Peptide gegen kälteunverträglichkeit hervorrufende autoantikörper und ihre verwendung | |
Pendergraft III et al. | Autoantigen complementarity and its contributions to hallmarks of autoimmune disease | |
US20040136988A1 (en) | Treatment of schizophrenia | |
US20030223995A1 (en) | Treatment of pemphigus vulgaris | |
US20030059428A1 (en) | Treatment of autoimmune diseases | |
US20030228310A1 (en) | Treatment of skin diseases | |
US20030086925A1 (en) | Treatment of autoimmune diseases | |
SELA | Therapeutic Vaccines Against Cancer and Autoimmune Diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20120918 |